TY - CHAP M1 - Book, Section TI - Chapter 90. Inflammatory Breast Cancer A1 - González, Viviana Negrón A1 - Oh, Julia L. A1 - Cristofanilli, Massimo A1 - Babiera, Gildy V. A2 - Kuerer, Henry M. PY - 2010 T2 - Kuerer's Breast Surgical Oncology AB - Inflammatory breast cancer (IBC) is one of the rarest and most aggressive forms of breast cancer, having relatively distinct clinicopathological features and the lowest survival rates. Its presentation was first described in 1814 by Bell as "a purple color on the skin over the tumor accompanied by shooting pains," which he identified as "a very unpropitious beginning."1 In 1889, Bryant noted the role of cancer cells obstructing the lymphatics in the development of inflammatory signs.2 The term "inflammatory carcinoma of the breast" was coined by Lee and Tannebaum in 1924. Currently, based on the American Joint Committee on Cancer (AJCC) Staging System, IBC is classified as T4d and described as a "clinicopathological entity that is characterized by diffuse erythema and edema (peau d'orange), often without an underlying mass. These clinical findings should involve the majority of the breast . . . "3 It should be stressed that IBC is primarily a clinical diagnosis and thus, in the absence of clinical findings, involvement of the dermal lymphatics alone does not indicate the diagnosis of IBC. In this chapter, we review the epidemiology, clinical presentation, diagnostic modalities, and treatment, and discuss the current controversies of IBC. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/03/28 UR - accesssurgery.mhmedical.com/content.aspx?aid=6417466 ER -